News Round-Up: "How I Treat" MDS from ASH Hematologic Malignancies and more

Tuesday, September 22, 2020

This week in Hematology and Oncology news:

  1. Large waistline linked to higher risk of prostate cancer death (https://bit.ly/3iRxmya)
  2. FOLFOXRI tops doublets as bevacizumab backbone for mCRC (https://bit.ly/32QpTKi)
  3. AI algorithm on par with radiologists as mammogram reader (https://bit.ly/35WnAXV)
  4. How I Treat: For low-risk MDS, treat 'what bugs patients most' (https://bit.ly/2ZU5TEU)

* * *

Find more Blood & Cancer at https://www.mdedge.com/podcasts/blood-cancer

Email the show at podcasts@mdedge.com

Podcast Participants

David Henry, MD
David Henry, MD, FACP, is a clinical professor of medicine at the University of Pennsylvania and vice chairman of the department of medicine at Pennsylvania Hospital in Philadelphia. He received his bachelor’s degree from Princeton University and his MD from the University of Pennsylvania, then completed his internship, residency, and fellowship at the Hospital of the University of Pennsylvania. After 2 years as an attending in the U.S. Air Force, he was drawn to practicing as a hem-onc because of the close patient contact and interaction, and his belief that, win or lose with each patient, one can always make a difference in their care and lives. Follow Dr. Henry on Twitter: @davidhenrymd. Dr. Henry reported being on the advisory board for Amgen, AMAG Pharmaceuticals, and Pharmacosmos. He reported institutional funding from the National Institutes of Health and FibroGen.